瑞舒伐他汀与阿托伐他汀在老年冠心病合并高脂血症治疗中的临床效果对比

Comparison of the Clinical Efficacy of Rosuvastatin and Atorvastatin in the Treatment of Elderly Coronary Heart Disease with Hyperlipidemia

目的:探究瑞舒伐他汀与阿托伐他汀在老年冠心病合并高脂血症治疗中的临床效果。方法:选取2015年9月至2021年2月我院医治的老年冠心病合并高脂血症患者180例,依据随机数字表法将其分为对照组和试验组,每组各90例。入院后两组患者均进行常规治疗,对照组患者给予口服阿托伐他汀,试验组患者给予口服瑞舒伐他汀,两组患者均连续治疗2个月。比较两组患者治疗前后心功能、血脂、炎性因子和内皮功能水平。结果:两组患者治疗前左心室舒张末内径(left ventricular end diastolic inner diameter,LVDd)、左心室收缩末内经(left ventricular end systolic diameter,LVDs)、左心室射血分数(left ventricular ejection fraction,LVEF)以及血清三酰甘油(triacylglycerol,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、超敏C-反应蛋白(high sensitivity C-reactive protein,hs-CRP)、白细胞介素-6(interleukin-6,IL-6)、内皮素-1(endothelin-1,ET-1)、非对称性二甲基精氨酸(asymmetric dimethylarginine,ADMA)、一氧化氮(nitric oxide,NO)水平差异均无统计学意义(P>0.05)。治疗后,两组患者LVDd、LVDs水平以及血清TG、TC、LDL-C、hs-CRP、IL-6、ET-1、ADMA水平均较治疗前降低(P<0.05),且试验组患者上述指标降低幅度较对照组更为明显(P<0.05)。治疗后两组患者LVEF水平及NO水平均较治疗前升高(P<0.05),且试验组患者上述指标升高幅度较对照组更为明显(P<0.05)。结论:相较于阿托伐他汀,瑞舒伐他汀更能保护老年冠心病合并高脂血症患者内皮功能,改善心功能,降低血脂水平,且抑制炎性因子产生,促进病情好转。

Objective:To explore the efficacy of rosuvastatin and atorvastatin in the treatment of elderly coronary heart disease with hyperlipidemia.Methods:180 elderly patients with coronary heart disease and hyperlipidemia in our hospital from September 2015 to February 2021 were selected and divided into the experimental group and the control group according to random number table method,90 cases in each group.After admission,the patients of both groups received routine treatment,and the control group took atorvastatin tablets,and the experimental group took rosuvastatin tablets.Both groups of patients were given continued treatment for 2 months.The heart function,blood lipids,inflammatory factors and endothelial function levels before and after treatment of the two groups were compared.Results:Before treatment,there was no statistically significant difference(P>0.05)between the two groups of patients in left ventricular end diastolic inner diameter(LVDd),left ventricular end systolic diameter(LVDs),left ventricular ejection fraction(LVEF),and serum triacylglycerol(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),endothelin-1(ET-1),asymmetric dimethylarginine(ADMA),nitric oxide(NO)levels.After treatment,the levels of LVDd,LVDs and serum TG,TC,LDL-C,hs-CRP,IL-6,ET-1,and ADMA of the two groups of patients were lower than those before treatment(P<0.05),and the above-mentioned index reduction of the exprerimental group were more obvious than those of the control group(P<0.05).After treatment,the LVEF and NO levels of the two groups of patients were higher than those before treatment(P<0.05),and the increase of the above indicators in the experimental group was more significant than that in the control group(P<0.05).Conclusion:Compared to atorvastatin,rosuvastatin could protect the endothelial function of elderly patients with coronary heart disease and hyperlipidemia,improve heart function,lower blood lipid levels,and inhibit the production of inflammatory factors,and promote the improvement of the condition.